NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Frontera Therapeutics

Frontera Therapeutics

Private
Bedford, MassachusettsHealthcare & Life Scienceshttps://fronteratherapeutics.com/

Last Round

Series B

Jul 19, 2022

Total Funding Raised

$230M

Company Overview

Frontera Therapeutics is a biotechnology company that develops and commercializes recombinant adeno-associated virus (rAAV) gene therapies for the treatment of genetic disorders in ophthalmology, cardiology, and neurology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapybiotechnologyGMP manufacturingrecombinant AAVrAAVclinical-stage biotechgenetic medicinedrug discoveryclinical trialsrare disease therapybiotech startuptherapeutic pipelinegood manufacturing practicebiotech venture

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Frontera Therapeutics Comparables

Compare Frontera Therapeutics with similar companies based on industry and business-model similarity.

Frontera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Exegenesis Bio
86%
Belief BioMed Inc.
83%
Avirmax, Inc.
80%

Frontera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 19, 2022

Frontera Therapeutics Investors

Notable investors and investment history

Frontera Therapeutics investors
InvestorRounds
Boyu CapitalSeries B
Creacion VenturesSeries B, Series A
Starr Investment HoldingsSeries B
OrbiMedSeries B, Series A
Starr Investments & BenefitsSeries B
TMCPSeries B
HongShan Capital Group (HSG)Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2025

    Will present gene therapy advances at the 2025 ASGCT Annual meeting.

  • Apr 22, 2025

    Will present gene therapy advances at the 2025 ARVO Annual meeting.

Frontera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Frontera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Frontera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBedford, Massachusetts
Employee Range21
Year Founded2019
Last FundingJul 19, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.